Please use this identifier to cite or link to this item: https://libjncir.jncasr.ac.in/xmlui/handle/10572/2083
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKaypee, Stephanie
dc.contributor.authorSudarshan, Deepthi
dc.contributor.authorShanmugam, Muthu K.
dc.contributor.authorMukherjee, Debanjan
dc.contributor.authorSethi, Gautam
dc.contributor.authorKundu, Tapas Kumar
dc.date.accessioned2017-01-24T06:20:41Z-
dc.date.available2017-01-24T06:20:41Z-
dc.date.issued2016
dc.identifier.citationKaypee, S.; Sudarshan, D.; Shanmugam, M. K.; Mukherjee, D.; Sethi, G.; Kundu, T. K., Aberrant lysine acetylation in tumorigenesis: Implications in the development of therapeutics. Pharmacology & Therapeutics 2016, 162, 98-119 http://dx.doi.org/10.1016/j.pharmthera.2016.01.011en_US
dc.identifier.citationPharmacology & therapeuticsen_US
dc.identifier.citation162en_US
dc.identifier.issn0163-7258
dc.identifier.urihttps://libjncir.jncasr.ac.in/xmlui/10572/2083-
dc.descriptionOpen Access (Accepted Manuscript)en_US
dc.description.abstractThe 'language' of covalent histone modifications translates environmental and cellular cues into gene expression. This vast array of post-translational modifications on histones are more than just covalent moieties added onto a protein, as they also form a platform on which crucial cellular signals are relayed. The reversible lysine acetylation has emerged as an important post-translational modification of both histone and non-histone proteins, dictating numerous epigenetic programs within a cell. Thus, understanding the complex biology of lysine acetylation and its regulators is essential for the development of epigenetic therapeutics. In this review, we will attempt to address the complexities of lysine acetylation in the context of tumorigenesis, their role in cancer progression and emphasize on the modalities developed to target lysine acetyltransferases towards cancer treatment. (C) 2016 Elsevier Inc. All rights reserved.en_US
dc.description.urihttp://dx.doi.org/10.1016/j.pharmthera.2016.01.011en_US
dc.language.isoEnglishen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.rights@Pergamon-Elsevier Science Ltd, 2016en_US
dc.subjectPharmacology & Pharmacyen_US
dc.subjectChromatinen_US
dc.subjectHistonesen_US
dc.subjectPost-translational modificationen_US
dc.subjectLysine acetylationen_US
dc.subjectLysine acetyltransferaseen_US
dc.subjectEpigenetic therapeuticsen_US
dc.subjectNf-Kappa-Ben_US
dc.subjectEpithelial-Mesenchymal Transitionen_US
dc.subjectAcute Myeloid-Leukemiaen_US
dc.subjectSmall-Molecule Inhibitoren_US
dc.subjectSquamous-Cell Carcinomaen_US
dc.subjectHistone Acetyltransferase Inhibitoren_US
dc.subjectCreb-Binding-Proteinen_US
dc.subjectCancer Stem-Cellsen_US
dc.subjectTranscription Factor Complexen_US
dc.subjectP300/Cbp Associated Factoren_US
dc.titleAberrant lysine acetylation in tumorigenesis: Implications in the development of therapeuticsen_US
dc.typeReviewen_US
Appears in Collections:Research Papers (Tapas K. Kundu)

Files in This Item:
File Description SizeFormat 
130-manuscript.pdf1.33 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.